Amwell (AMWL) Q2 2026 earnings review
Profitability in Sight as Top-Line Contraction Slows
Amwell delivered a strong beat on profitability, narrowing its Adjusted EBITDA loss to just $1.2M—a dramatic improvement from a $4.7M loss a year ago. Revenue of $52.0M hit the top end of guidance, though it still represents a 26% YoY contraction. The market's focus, however, is on the bottom line and structural positioning. Management successfully raised full-year Adjusted EBITDA guidance, reiterated its Q4 cash flow breakeven target, and announced a major catalyst: the Defense Health Agency (DHA) intends to make Amwell a prime contractor. The business is shrinking, but it is surviving and establishing a viable floor.
🐂 Bull Case
The company is accelerating toward profitability, improving Adjusted EBITDA to practically breakeven (-$1.2M). Management confidently raised full-year EBITDA guidance and reiterated the goal of positive operating cash flow by Q4 2026.
The Defense Health Agency announced its intent to elevate Amwell to a prime contractor. This is a massive endorsement of the platform's security and capabilities, securing the company's most critical government relationship.
🐻 Bear Case
Revenue declined 26% YoY to $52.0M, and Q3 guidance ($46M-$48M) implies further sequential deterioration. The platform is bleeding scale as it transitions.
Total platform visits plummeted 33% YoY, falling from 1.2 million in 25Q2 to just 0.8 million in 26Q2. The structural shift away from low-acuity urgent care is heavily depressing platform utilization.
⚖️ Verdict: ⚪
Neutral. The operational restructuring is a success: Amwell is proving it can halt its cash burn. However, an investment case relies on future growth, and with total visits down 33% and revenue still shrinking, the top-line recovery remains entirely theoretical.
Key Themes
DHA Endorsement Upgrades Government Pipeline
Management revealed that the Defense Health Agency intends to make Amwell a prime contractor. This is a significant upgrade from a subcontractor role, structurally improving contract economics and establishing Amwell as a validated, enterprise-grade vendor for other federal and state agencies. It drastically reduces renewal risk for their most important customer.
Ruthless Cost Controls Yield Profitability
The turnaround narrative is firmly backed by data. Total costs and operating expenses dropped from $91.2M in 25Q2 to $61.6M in 26Q2 (down 32%). Sales & Marketing was slashed by over 50% ($5.8M vs $12.5M). These aggressive cuts allowed the company to raise its FY26 Adjusted EBITDA guidance from a midpoint of -$14M to -$8M, accelerating the timeline to positive cash flow.
Visit Volume Freefall Contradicts Platform Stickiness
Management consistently touts the transition to an essential, sticky enterprise platform. Yet, total platform visits dropped to 0.8 million in 26Q2, representing a stark deceleration from 1.0M in 26Q1 and 1.2M in 25Q2. If the platform is truly becoming a unified digital front door for health systems, overall utilization volume should not be contracting at a 33% YoY rate.
Subscription Mix Shift Complete
Subscription revenue hit $25.7M, representing 49.4% of total revenue. This is a massive structural shift compared to prior years when transaction-based visit revenue dominated. The resulting revenue base is smaller but vastly more predictable, providing the exact stability needed to navigate to cash-flow breakeven.
AI as the Underlying Infrastructure
Amwell continues to position its Converge platform not as a standalone AI feature, but as the secure, governed environment where clients deploy third-party 'agentic AI' tools. By acting as the regulated rails for health tech innovation, the company is attempting to make itself immune to 'vendor sprawl' and indispensable to large payers.
Macro: Broader Telehealth Market Weakness
The company explicitly cites 'weak growth and increased volatility in the telehealth market' as a forward-looking risk factor. With hospital budgets constrained and the initial pandemic-era surge long gone, selling new digital health infrastructure requires overcoming intense market fatigue, complicating the path to re-accelerating the top line.
Other KPIs
Reversing. Gross margin improved sequentially from 51.0% in 26Q1 to 53.0% in 26Q2. While still below the 56.1% achieved in the prior year period (which was temporarily boosted by non-recurring implementation revenue), the stabilization is a positive indicator that the new baseline unit economics are sound.
Stable. The company maintains an unencumbered balance sheet with zero debt. Total cash and equivalents increased sequentially due to working capital dynamics and disciplined burn, easily providing enough liquidity to bridge the gap to operational self-funding in Q4.
Stable. Despite total platform visits dropping dramatically, AMG visit revenue remained surprisingly resilient, driven by a higher-acuity mix (like Virtual Primary Care) yielding higher revenue per visit.
Guidance
Accelerating slightly vs prior guidance. The company raised the low end of its revenue outlook from $195M to $200M. The midpoint implies roughly a 20% YoY decline from FY25's $249M, confirming that the top-line reset is priced in.
Accelerating. A massive improvement. Previously guided to a loss of ($16M) to ($12M). The company is stripping costs out faster than anticipated, heavily derisking the Q4 cash flow target.
Decelerating. A sequential step down from Q2's $52.0M. This indicates that the legacy churn and divestiture impacts are not completely flushed out of the quarterly run rate yet.
Decelerating. A slight sequential regression from the stellar ($1.2M) print in Q2, entirely expected given the projected lower sequential revenue base for the third quarter.
Key Questions
DHA Prime Contract Economics
The intent to make Amwell a prime contractor is a major win. How will this structural change impact the margin profile and revenue recognition of the DHA contract compared to the previous subcontractor arrangement?
Bridging the Q3 Revenue Decline
With Q2 revenue at $52M, guidance for Q3 implies a notable sequential drop to $46-$48M. What specific legacy churn or contract roll-offs are driving this final step down before the base stabilizes?
Visit Volume Floor
Total platform visits declined 33% YoY to 0.8 million. Is the current volume mix solely high-value, high-acuity visits, or should investors expect further declines in volume as legacy low-acuity urgent care programs are entirely phased out?
Growth Vectors for 2027
With cash flow breakeven practically secured for Q4, what are the primary commercial levers you are pulling today to ensure top-line revenue growth actually re-accelerates in 2027?